The patent provides protection for the use of cobitolimod in the treatment of inflammatory bowel disease.
The patent (patent number: 10-2592716) will provide an exclusivity period until
Corresponding patent applications have previously been granted in
Contact:
Tel: +46 8 122 038 50
Email: jenny.sundqvist@indexpharma.com
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III program CONCLUDE as a novel treatment of moderate to severe left-sided ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.
InDex is based in
(C) 2023 Electronic News Publishing, source